Physician profile
Mark Hancock
NPI 1003954637
$5,743.57
in general payments reported to CMS, 2019-2025
50 companies · $987 in 2025
The $987 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $186 · 2021: $49.99 · 2022: $532 · 2023: $1,461 · 2024: $1,430 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,718 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.28 |
| Education | $159.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $922.01 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals LP | $474.17 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Pfizer INC. | $414.70 | 2019-2025 | |
| Exelixis INC. | $365.76 | 2019-2024 | |
| Caris Mpi, INC. | $344.09 | 2025 | Mi Cancer Seek |
| Janssen Scientific Affairs, LLC | $341.21 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $299.16 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $286.18 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Lilly USA, LLC | $264.18 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $190.55 | 2022-2025 | Reblozyl, Breyanzi, Onureg |
| Daiichi Sankyo INC. | $177.27 | 2022 | |
| Amgen INC. | $130.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $93.85 | 2019-2024 | |
| Genzyme Corporation | $89.27 | 2019-2024 | |
| Servier Pharmaceuticals LLC | $81.18 | 2023-2024 |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.